SGRY — Surgery Partners, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Care Facilities·USA

Latest market price

16.06

+0.66+4.29%

Overview Short InterestFilings

SGRYQT51Surgery Partners, Inc.·NASDAQ

Overview Short InterestFilings

16.06+4.29%

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AVAH+2.34%$9.61 SEM-0.12%$16.51 ADUS+1.13%$116.79 MD-0.98%$26.25 ASTH+0.98%$35.91 GRDN+3.24%$40.81 HCSG+0.47%$23.41 INNV-1.14%$11.23

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.59	Insider Own	-	Shs Outstand	130.79M	Perf Week	-2.10%

Market Cap	2.01B	Forward P/E	24.52	EPS next Y	0.63	Insider Trans	-0.04%	Shs Float	77.94M	Perf Month	-7.23%

Enterprise Value	5.86B	PEG	-	EPS next Q	-	Inst Own	125.12%	Short Float	18.99%	Perf Quarter	9.76%

Income	-77.54M	P/S	0.60	EPS this Y	172.72%	Inst Trans	-	Short Ratio	10.36	Perf Half Y	6.35%

Sales	3.34B	P/B	1.17	EPS next Y	46.38%	ROA	-0.95%	Short Interest	14.80M	Perf YTD	-0.32%

Book/sh	-	P/C	7.06	EPS next 5Y	40.11%	ROE	-4.43%	52W High	25.13 -36.10%	Perf Year	-31.16%

Cash/sh	-	P/FCF	9.68	EPS past 3/5Y	-	ROIC	4.60%	52W Low	11.90 34.97%	Perf 3Y	-60.77%

Dividend Est.	-	EV/EBITDA	6.12	Sales past 3/5Y	9.23% 12.21%	Gross Margin	21.68%	Volatility	4.74% 4.97%	Perf 5Y	-72.67%

Dividend TTM	-	EV/Sales	1.75	EPS Y/Y TTM	55.64%	Oper. Margin	12.26%	ATR (14)	0.78	Perf 10Y	-12.85%

Dividend Ex-Date	-	Quick Ratio	1.69	Sales Y/Y TTM	7.39%	Profit Margin	-2.28%	RSI (14)	47.63	Recom	2.36

Dividend Gr. 3/5Y	-	Current Ratio	1.86	EPS Q/Q	-	SMA20	-3.86%	Beta	1.89	Target Price	19.33

Payout	0.00%	Debt/Eq	2.39	Sales Q/Q	4.51%	SMA50	1.79%	Rel Volume	0.74	Prev Close	15.40

Employees	16,000	LT Debt/Eq	1.10	Earnings	Aug 10	SMA200	-0.38%	Avg Volume	1.54M	Price	16.06

IPO Date	Sep 30, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	75.90% 1.66%	Net Debt/EBITDA	4.01	Volume	1,137,880	Change	4.29%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-06-26	Reiterated	Jefferies	Buy	$15 → $17
Apr-20-26	Reiterated	Jefferies	Buy	$16 → $15
Mar-11-26	Reiterated	US Capital Advisors		$21
Mar-04-26	Reiterated	Jefferies	Buy	$30 → $16
Mar-04-26	Reiterated	RBC Capital	Outperform	$20
Mar-03-26	Reiterated	Jefferies	Buy	$40 → $30
Dec-18-25	Reiterated	Mizuho	Outperform	$22 → $19
Nov-21-25	Reiterated	Barclays	Equal Weight	$31 → $18
Nov-17-25	Reiterated	Mizuho	Outperform	$22
Nov-13-24	Reiterated	Jefferies	Buy	$40

Latest News

Jul-30-26

Jul-30-2607:11AM

Strength Seen in Surgery Partners (SGRY): Can Its 5.3% Jump Turn into More Strength?zacks.com

Jul-24-26

Jul-24-2612:56PM

Surgery Partners Monetizes Idaho Assets As It Chases Faster GrowthBenzinga

09:00AM

Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transactionglobenewswire.com

Jul-14-26

Jul-14-2601:20PM

Pediatrix Medical Group shares are trading lower after the company reported mixed Q4 financial results.Benzinga

Jul-08-26

Jul-08-2609:56AM

Fast-paced Momentum Stock Surgery Partners (SGRY) Is Still Trading at a Bargainzacks.com

Company

Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical venues include both ambulatory surgery centers and dedicated surgical hospitals, delivering non-urgent surgical procedures across various specialties such as gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The surgical hospitals additionally offer comprehensive ancillary services, including diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care. The dedicated Ancillary Services segment further encompasses multi-specialty physician practices, urgent care facilities, and anesthesia services. By December 31, 2021, the company's portfolio consisted of 126 surgical facilities—specifically, 108 ambulatory surgical centers and 18 surgical hospitals—situated across 31 states. Founded in 2004, Surgery Partners, Inc. maintains its headquarters in Brentwood, Tennessee.

Ownership

Total institutional ownership125.12%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	3,344	3,309	3,114	2,743	2,539	2,225	1,860	1,831	1,771
Cost of Goods Sold Incl. D&A	2,619	2,544	2,369	2,096	1,964	1,734	1,480	1,408	1,361
Gross Profit	725	765	746	648	575	491	380	424	410
Selling, General and Administrative Excl. Other	628	523	139	121	102	104	97	89	94
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	-313	-147	258	199	128	85	100	99	63
Operating Income	410	390	349	328	345	302	183	236	78
Interest Expense	667	273	202	193	235	221	202	179	147
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	370	0	0	0	0	0	0	-2	0
Net Income Before Taxes	115	117	147	135	110	81	-19	55	-69
Income Taxes	18	18	135	0	23	11	-20	10	26
Consolidated Net Income	-76	-78	-168	-12	-55	-71	-116	-75	-206
Net Income From Continuing Operations	97	99	13	135	87	71	1	45	-96
Net Income	-76	-78	-168	-12	-55	-71	-116	-75	-206
EPS (Recurring)	-0.59	-0.61	-1.33	-0.09	-0.59	-1.12	-3.19	0.95	-4.28
EPS (Basic, Before Extraordinaries)	-0.59	-0.61	-1.33	-0.09	-0.59	-1.12	-3.19	0.95	-4.28
EPS (Diluted)	-0.59	-0.61	-1.33	-0.09	-0.59	-1.12	-3.19	0.95	-4.28
EBITDA	958	566	501	446	460	401	278	310	145
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	16.48	—
Price To Sales Ratio	0.61	0.59	0.86	1.47	1.01	1.73	0.76	0.41	0.27
Gross Margin	21.68	23.12	23.96	23.62	22.65	22.07	20.43	23.16	23.15
Operating Margin	12.26	11.79	11.21	11.96	13.59	13.57	9.84	12.89	4.40
Net Margin	-2.27	-2.36	-5.39	-0.44	-2.17	-3.19	-6.24	-4.10	-11.63
Shares Outstanding	128	127	126	126	92	72	49	48	48
Market Capitalization	2,056	1,962	2,667	4,031	2,563	3,846	1,421	751	470
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Doherty David T	Chief Financial Officer	Mar 16 '26	Sale	12.50	8,867	110,838	221,679	Mar 16
Evans Jason Eric	Chief Executive Officer	Mar 16 '26	Sale	12.47	20,400	254,388	920,386	Mar 16
Burkhalter Danielle	Chief Human Resources Officer	Mar 13 '26	Sale	12.83	3,469	44,507	76,864	Mar 16
Brittenham Marissa	Chief Strategy Officer	Mar 13 '26	Sale	12.54	3,657	45,859	94,196	Mar 16
Baldock Jennifer	Chief Admin & Dev Officer	Mar 12 '26	Sale	13.17	5,798	76,360	326,474	Mar 16
Baldock Jennifer	Chief Admin & Dev Officer	Mar 06 '26	Sale	13.70	10,082	138,123	332,272	Mar 09
Evans Jason Eric	Chief Executive Officer	Mar 06 '26	Sale	13.79	11,462	158,061	662,680	Mar 09
Doherty David T	Chief Financial Officer	Mar 06 '26	Sale	13.84	14,574	201,704	88,803	Mar 09
Burkhalter Danielle	Chief Human Resources Officer	Mar 06 '26	Sale	13.60	7,736	105,210	37,103	Mar 09
Webb William Trenton	American Group President	Mar 06 '26	Sale	13.93	272	3,789	74,249	Mar 09
Brittenham Marissa	Chief Strategy Officer	Mar 06 '26	Sale	13.70	8,785	120,355	54,623	Mar 09
Webb William Trenton	American Group President	Mar 05 '26	Sale	13.86	1,794	24,865	72,455	Mar 09
Bane Harrison R.	National Group President	Sep 04 '25	Sale	22.48	9,339	209,940	117,181	Sep 08
Maryland Patricia Anne	Director	Aug 11 '25	Sale	22.74	20,018	455,209	4,565	Aug 15
DeLuca Teresa	Director	Aug 11 '25	Sale	22.74	20,018	455,209	45,173	Aug 15

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.